Tirzepatide combines GIP with GLP-1 activity and can produce similar modest pulse rises and GI effects
New England Journal of Medicine, 387 (3), 205-216.
According to the UK Summary of Product Characteristics (SmPC), the most commonly reported adverse reactions include nausea, diarrhoea, vomiting, constipation, abdominal pain, and decreased appetite
de C.V., received a warning letter on June 13, 2022, for refusing to allow FDA entry to conduct an on-site inspection
While weekly injections have become increasingly accepted, they remain a barrier for many patients who are reluctant to start or maintain long-term therapy
People with sensitivities to supplements or those taking L-carnitine derived from certain sources may be at higher risk